Clinical Trials Logo

Flare Up, Symptom clinical trials

View clinical trials related to Flare Up, Symptom.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03394586 Recruiting - Ulcerative Colitis Clinical Trials

Real-world Data Regarding Treatment of Ulcerative Colitis Patients With Golimumab

Start date: January 1, 2018
Phase: N/A
Study type: Observational [Patient Registry]

TNF inhibitors have improved treatment options for patients with inflammatory bowel disease (IBD) and three TNF inhibitors, infliximab, adalimumab and golimumab are available for treatment of ulcerative colitis in Switzerland. However, these drugs have been tested under ideal conditions in randomized controlled trials. Real-world data are needed to complement this information. It is the aim of our study to test, whether patients with ulcerative colitis can be effectively treated with golimumab in a real world setting in Switzerland. The investigators will use data from the Swiss IBD cohort study (SIBDC) in Switzerland. They will identify all SIBDC patients with UC treated with Golimumab and perform a retrospective chart review. The investigators will acquire patient reported outcomes and objective measures for inflammation at baseline, at 6-10 weeks and at 6 and 12 months after golimumab treatment. Primary endpoint will be clinical response (i.e. meaningful improvement) at 6-10 weeks. Secondary endpoints will be clinical response at 6 and 12 months and clinical remission (i.e. free of symptoms of disease).